HORMONAL THERAPY AND THE RISK OF RHEUMATIC AUTOIMMUNE DISEASES AMONG OLDER MEN WITH PROSTATE CANCER
Mohanad Albayyaa · 2024
Read HORMONAL THERAPY AND THE RISK OF RHEUMATIC AUTOIMMUNE DISEASES AMONG OLDER MEN WITH PROSTATE CANCER by Mohanad Albayyaa (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11691370.txt.
Description
Mohanad Albayyaa asks whether hormonal therapy for prostate cancer raises the risk of rheumatic autoimmune diseases in older men. The therapy, androgen deprivation, cuts male hormones and is a mainstay of care, yet it stirs immune cells and inflammatory markers. His 2024 study uses a Texas cancer registry linked to Medicare claims, covering men aged 66 and older with localized cancer from 2010 to 2019. Men who received the therapy were matched one to one with men who did not.
Disease rates ran 11 percent in the therapy group against 9 percent without it. A risk model set the increase at 1.29-fold, with a firm confidence band. Four diseases make up the class: rheumatoid arthritis, lupus, ankylosing spondylitis, and Sjögren's syndrome. His advice: warn men up front, watch them closely, and tailor care plans to each man.
Catalog record
| CREATOR | Mohanad Albayyaa |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |